**Differential effect of LPS on glucose, lactate and inflammatory markers in the lungs of normal and diabetic mice**

Cecilia Nagorny-Holmberg1, Annika Åstrand1, Cecilia Wingren1, James P. Garnett2, Gaëll Mayer1, John D. Taylor1, Emma H. Baker2 & Deborah L. Baines2\*

1Respiratory, Inflammation and Autoimmunity Innovative Medicines Research Unit, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. 2 Institute for Infection and Immunity, St George’s, University of London, London SW17 0RE, UK.

\*Corresponding author:

[dbaines@sgul.ac.uk](mailto:dbaines@sgul.ac.uk)

**Running Head: Effect of LPS on lung glucose**

**Abstract**

Elevation of blood glucose results in increased glucose in the fluid that lines the surface of the airways and this is associated with an increased susceptibility to infection with respiratory pathogens. Infection induces an inflammatory response in the lung, but how this is altered by hyperglycaemia and how this affects glucose, lactate and cytokine concentrations in the airway surface liquid is not understood.

We used wild type (WT) and glucokinase heterozygote (GK+/-) mice to investigate the effect of hyperglycaemia, with and without LPS-induced inflammatory responses, on airway glucose, lactate, inflammatory cells and cytokines measured in brochoalveolar lavage fluid (BALF).

We found that glucose and lactate concentrations in BALF were elevated in GK+/- compared to WT mice and that there was a direct correlation between blood glucose and BALF glucose concentrations. LPS challenge increased BALF inflammatory cell numbers and this correlated with decreased glucose and increased lactate concentrations although the effect was less in GK+/- compared to WT mice. All cytokines measured (except IL-2) increased in BALF with LPS challenge. However, concentrations of TNFα, INFγ, IL-1β and IL-2 were less in GK+/- compared to WT mice.

This study shows that the normal glucose/lactate environment of the airway surface liquid is altered by hyperglycaemia and the inflammatory response. These data indicate that inflammatory cells utilise BALF glucose and that production of lactate and cytokines is compromised in hyperglycaemic GK+/- mice.

**Key words:** airway, glucose, metabolism, hyperglycaemia, inflammation

**Abbreviations:** Wild type (WT), glucokinase (GK), airway surface liquid (ASL), broncheoalveolar lavage (BAL) fluid (BALF), lipopolysaccharide (LPS), tumor necrosis factor (TNF), interferon (INF), interleukin (IL), phosphate buffered saline (PBS), meso scale discovery (MSD), white blood cells (WBC), chronic obstructive disease (COPD), cystic fibrosis (CF)

**Introduction**

There is mounting evidence that raised blood glucose concentrations (hyperglycaemia) as a result of diabetes mellitus or severe illness (stress hyperglycaemia) are associated with increased susceptibility to respiratory infections, particularly when associated with underlying respiratory disease [[1-4](#_ENREF_1)]. Glucose concentration in the fluid that lines the luminal surface of the airways (airway surface liquid, ASL) is in normal situations low at ~0.4 mM. However, we have shown that elevation of blood glucose leads to increased glucose concentration in ASL (up to ~4.0 mM) in nasal and bronchial secretions in patients [[1](#_ENREF_1), [3](#_ENREF_3), [5](#_ENREF_5), [6](#_ENREF_6)]. Glucose was also elevated in bronchoalveolar lavage fluid (BALF) from the lungs of a mouse model of diabetes (the leptin receptor deficient db/db mouse) compared to wild type [[7](#_ENREF_7)]. Elevation of glucose was associated with increased *Staphylococcus aureus* and *Pseudomonas aeruginosa* in the airway and we have shown that sugars in the ASL can be utilised by these bacteria as a nutrient source for growth [[8-10](#_ENREF_8)].

Inflammatory stimuli increases the permeability of the epithelium to glucose, elevating glucose diffusion from blood into the ASL [[9](#_ENREF_9)]. Inflammatory stimuli also increase activation and genesis of inflammatory cells and their recruitment to the airway lumen [[7](#_ENREF_7), [11](#_ENREF_11)]. Thus, glucose in the ASL potentially supplies a local nutrient source for inflammatory cells of the respiratory tract. Hyperglycaemia has also been shown to modify inflammatory responses in the lung [[12](#_ENREF_12), [13](#_ENREF_13)]. We hypothesised that the availability of glucose in the ASL and its metabolism by inflammatory cells could contribute to this effect. In addition, if inflammatory cells utilise glucose this would reduce glucose concentration in ASL and affect the concentration of other metabolites such as lactate.

Here, we investigated the relationship between blood glucose and glucose concentration in the BALFs of normal (WT) and hyperglycaemic (glucokinase deficient, GK+/-) mice and studied how this relationship, the concentration of lactate, production of cytokines and the inflammatory responses changed when the lungs were challenged with bacterial lipopolysaccharide.

**Materials and methods**

Male and female (17 weeks old, average weight 24±3 g) heterozygote GK+/- mice on C57/Bl6 background and wild type C57/Bl6 mice were used in the study [[14](#_ENREF_14)]. Animals were kept in a facility with 12h light/dark cycle at 21±2°C and with 55±15% relative humidity. Water and normal rodent chow were available *ad libitum.*

WT and GK+/- mice were randomized into treatment groups of 4, 24 and 48 hours post LPS challenge versus no challenge (indicated as time 0) using 4-5 animals per group. Experiments were repeated for 0 and 48 hours to obtain additional samples for cytokine analysis and results from these studies were pooled. LPS from P.*aeruginosa* (Sigma-Aldrich, USA) was previously frozen in 1 mg/ml aliquots and diluted to the concentration needed to give 0.0875 μg/g mouse in 50 μl (based on the average weight of the group) and given by intranasal dosing at time 0. In brief, animals were anaethetised with isoflurane 4-5% (O2 1.2 l/min) prior to administration of the LPS solution to one nostril, which was subsequently inhaled naturally. Mice were then returned to their cages when retaining consciousness.

Body weight was recorded once daily from 0-48 hours after administration of LPS to follow the wellbeing of the animals. Blood was collected from the vena saphena in conscious mice for glucose evaluation after 4 hours of fasting. At 4, 24 or 48 hours after LPS administration, the animals were terminated with an overdose of pentobarbital (0.2 ml of 100 mg/ml i.p.). The lungs of each animal were subjected to bronchoalveolar lavage (BAL). In brief, the trachea was exposed and a catheter inserted into the trachea through a cut between two upper cartilage rings below the larynx. The catheter was secured with a silk suture and three volumes of 0.3 ml saline were instilled, gently aspirated, pooled and weighed.

The BAL fluid (BALF) was centrifuged (Sorvall Rotanta 46R, Hettich Zentrifugen, Tullingen, Germany, 1200 rpm (314g), 10 min, 4°C). The pellet was re-suspended in 0.25 ml of PBS and the total and differential cell count was performed using SYSMEX XT-1800i Vet. (SYSMEX, Kobe Japan). Cell count is expressed as the amount of cells per ml of recovered BALF. The supernatant was used to measure glucose and lactate on the ABX Pentra 400 (Horiba ABX Medical, Kyoto, Japan) according to the manufacturer’s protocol. Inflammatory cytokines in the supernatant were analysed by means of an MSD 10-plex (K15048D-1 MSD mouse Pro inflammatory panel (V-plex), Mesoscale Discovery, Maryland, US).

At termination, blood from behind the eye was collected in EDTA tubes and blood glucose was measured directly using Accu-check (Roche, Bromma, Sweden). Plasma lactate was assayed using the ABX Pentra 400.

All experiments were approved by the local Ethical committee in Gothenburg (184-2012).

**Statistical analysis**

Values are reported as the mean±SEM. Statistical analysis was performed using analysis of variance (ANOVA) tests followed by Bonferroni multiple comparison post hoc tests (GraphPad Prism) or Student’s *t* test. *P* values of <0.05 were considered statistically significant.

**Results**

**Characterisation of airway glucose metabolism**

Fasting blood glucose was higher in GK+/- than wild type (WT) mice (15.2±4.9 compared to 9.4±0.19 mM, p<0.0001, n=25) (Fig 1a). Blood glucose remained higher in GK+/- mice compared to WT 48 hours after treatment with LPS although the concentration of glucose was reduced to 11.7±0.6 and 7.7±0.2 mM, respectively (p<0.0001, n=17). There was no significant difference in plasma insulin levels between WT and GK+/- mice (0.59±0.12 and 0.47±0.1 ng/ml, respectively, n=9). There were also no significant changes in blood lactate concentration in WT or GK+/- at any of the time points tested (Fig 1b).

Glucose concentration in the BALF of GK+/- mice was significantly higher than that of WT mice (0.15±0.2 compared to 0.03±0.004 mM, p<0.0001, n=19). It remained higher in the GK+/- mice following LPS challenge, but at significantly lower levels for both mouse types (p<0.001 at 24 and 48 hours, n=4 and 14, respectively). We could not detect any measureable glucose in BALF from WT mice at 24 hours (Fig 1c). There was a significant relationship between blood glucose/BALF glucose concentration prior to treatment with LPS and independent of mouse type (p<0.0001, n=44). However, this relationship was lost 48 hours after treatment with LPS (p<0.05, F=6, Df=73) (Fig 2a).

Lactate concentration in the BALF of GK+/- mice was significantly higher than WT in the absence of an inflammatory stimulus (0.1±0.008 compared to 0.07±0.007 mM, p<0.05, n=19) (Fig 1d).As expected, the concentration of lactate in the BALFs of GK+/- and WT mice increased after treatment with LPS. Less so in the GK+/- mice, only reaching significance after 48 hours (p<0.01, n=16), whereas lactate concentration was significantly increased at 24 and 48 hours in WT mice (p<0.0001, n=3 and n=16, respectively). There were also higher concentrations of lactate in WT compared to GK+/- mice at 48 hours (p<0.01, n=15) whereas the difference at 24 hours was borderline significant (p=0.059, n=4). Thus, less lactate was produced in the lungs of GK+/- mice after an inflammatory stimulus than in WT mice (Fig 1d).

There was no relationship between blood lactate and BALF lactate but there was a small positive relationship between blood glucose and BALF lactate (p<0.01, n=41) at baseline (Fig 2b). This relationship was completely reversed 48 hours after treatment with LPS where lactate in the BALF decreased with increasing blood glucose (p<0.01, n=29) (Fig 2b), similarly for both mouse types.

**Impact of hyperglycaemia on airway response to lipopolysaccharide**

Prior to LPS treatment, GK+/- mice had similar numbers of inflammatory cells (total white blood cells (WBC) including lymphocytes, macrophages, neutrophils and eosinophils) in the BALF as compared to WT.

Treatment of GK+/- with LPS elicited an increase in inflammatory cells recovered from the BAL which was maximal at 24-48 hours. The absolute numbers of lymphocytes and neutrophils were similarly increased in WT and GK+/- at 4, 24 and 48 hours versus untreated controls. Macrophages in the BALF were not elevated until 24 hours post LPS treatment and to a similar extent in WT and GK+/- mice (Fig 3a-c). Interestingly, 24 hours post LPS treatment, eosinophils were significantly reduced in GK+/- compared to WT mice (p<0.01, n=3) indicating that the elevation of blood glucose in these mice could influence eosinophil recruitment and/or survival (Fig 3d).

There was a negative correlation of WBC with BALF glucose in WT and GK+/- mice (p<0.05, n=40 and p<0.001, n=47, respectively) (Fig 2c). As white blood cell number increased, glucose in the BALF decreased and this was more pronounced in GK+/- mice. As expected, the number of WBC positively correlated with BALF lactate concentration, similarly in WT and GK+/- mice (p<0.05, n=41 and p<0.01, n=48, respectively) (Fig 2d). We found similar relationships with macrophages and neutrophils, the most numerous cells in BALF, indicating that these were the main source of lactate. There was an indication that the slope of the line was reduced and that less lactate was produced by the inflammatory cells in GK+/- compared to WT mice, however, we were unable to attribute significance to this observation (p=0.08). Interestingly, eosinophils in WT mice showed a positive association with lactate (p<0.0001, n=39) but this was not observed in GK+/- mice (Fig 1d and Fig 3d).

**Hyperglycaemic airways and secretion of cytokines in response to respiratory challenge**

As the greatest differences in the parameters tested were identified at 48 hours post LPS challenge, we then investigated cytokine concentration in the BALFs of challenged and unchallenged animals. There were almost no production of cytokines into the BALF of untreated WT and GK+/- mice, consistent with the lack of inflammatory cells. LPS challenge for 48 hours significantly increased the concentration of TNFα, IL-1β, IL-6, IL-8 and INFγ (Fig 4a-f). IL-2 concentrations were lower than other cytokines and showed no elevation with LPS treatment (Fig 4d). There was significantly less IL-2, IL-1β and TNFα in the BALFs of GK+/- compared to WT mice 48 hours after LPS treatment (p<0.01, n=8-10 respectively).

**Discussion**

The present study demonstrates increased respiratory glucose concentration in a further hyperglycaemic mouse model of human diabetes, in line with previous reports including human disease [[1](#_ENREF_1), [3](#_ENREF_3), [7](#_ENREF_7), [10](#_ENREF_10), [15](#_ENREF_15)]. Also here, we show a positive and significant correlation of airway glucose levels with increasing blood glucose concentrations, but no impact on inflammatory cells or cytokine release in the unchallenged situation. Exposure to lipopolysaccharide (LPS) completely changes the blood/BALF glucose relationship. Glucose concentration falls and lactate rises as inflammatory cell numbers increase. We propose that inflammatory cells utilise the available glucose and increase the production of lactate. This effect is altered with hyperglycaemia. Lactate concentration is lower and goes in hand with less cytokine production and recruitment of eosinophils. These data indicate a defective/suppressed response in hyperglycaemic lungs to respiratory infections.

We have used a mouse model of hyperglycaemia (the glucokinase heterozygous knockout model, GK+/-) which exhibit impaired glucose tolerance and diminished insulin secretion in response to glucose resulting in raised blood glucose concentration [[16](#_ENREF_16), [17](#_ENREF_17)]. These mice do not exhibit obesity or hyperinsulinemia that is associated with the leptin and leptin receptor deficient models of type II diabetes such as the ob/ob and db/db mouse [[18](#_ENREF_18), [19](#_ENREF_19)]. In this mouse, and similar to our findings *in vivo* and *in vitro*, raised blood glucose is associated with increased glucose in bronchoalveolar lavage fluid (BALF)/ASL (airway surface liquid) and there is a positive relationship between blood glucose concentration and glucose in BALF. It is difficult to calculate the volume of mouse lung ASL and thus the absolute concentration of glucose without using dilution markers. However, a mouse of the weight used in these experiments would likely have a surface area of 70cm2 [[20](#_ENREF_20), [21](#_ENREF_21)]. Airway surface liquid has been proposed to be a depth of 8-35 m depending on the radius of the airway [[21](#_ENREF_21), [22](#_ENREF_22)] and alveolar fluid depths are much smaller at 0.1m [[23](#_ENREF_23)]. A contribution of 50:50 alveolar:airway surface liquid to BALF glucose would give an estimate of 0.48 mM glucose in ASL from WT mice and 1.5mM in GK+/- mice. Even if it is assumed that most of the sampling is from the distal lung i.e. 90:10 alveolar:airway, the resultant glucose concentrations are still calculated to be significantly less than corresponding blood glucose in accordance with our previous *in vivo* and *in vitro* studies [[3](#_ENREF_3), [9](#_ENREF_9)].

Treatment of mice with LPS induced a robust inflammatory response as indicated by the elevation in inflammatory cells and pro-inflammatory cytokines in the BALF. Inflammatory cell numbers after LPS challenge were similar in GK+/- compared to WT mice except for eosinophils which were reduced. Similarly, eosinophils but not neutrophils, were reduced in ovalbumin challenged lungs of diabetic ob/ob mice [[24](#_ENREF_24)]. No difference in lung neutrophils was shown in diabetic Zucker rat lungs after tracheal instillation of LPS or in diabetic Wistar rats compared to wildtype [[12](#_ENREF_12), [13](#_ENREF_13)]. Thus, hyperglycaemia appears to effect eosinophil recruitment to the lung.

LPS challenge decreased BALF glucose over 48 hours. Although, blood glucose declined with the inflammatory response [[25](#_ENREF_25)] this was unlikely to be the cause of the change in BALF glucose as the relationship between blood and BALF glucose was lost and BALF glucose concentrations were much lower than expected for the corresponding blood glucose after LPS treatment. There was however, a clear inverse relationship between glucose concentration and number of inflammatory cells/lactate in BALF. A previous study in rats showed that tracheal instillation of LPS increased glucose utilisation by white blood cells (WBC) in the airways [[26](#_ENREF_26)]. This was mostly explained by increased numbers of neutrophils which had high glucose utilisation and a doubling of glucose utilisation by activated macrophages [[26](#_ENREF_26)]. In our study, neutrophils and macrophages were the predominant cells post LPS treatment. In rats, glucose utilisation by activated macrophages and PMNs increased to ~7.5 and 1.75nmols/min/106 cells, respectively. We had approximately 2 x 106 macrophages plus neutrophils in the mouse BALF 48 hours after LPS treatment. If rat and mouse models are similar, then glucose utilisation would be ~18 nmole/min. WT BALF contained 35 nmoles of glucose which would be depleted rapidly by LPS activated inflammatory cells. Thus, utilisation of glucose by inflammatory cells would account for the reduced glucose concentration in the BALF after LPS challenge. This hypothesis now needs to be tested to establish if this is indeed the case.

Glucose remained detectable in the BALF (except in WT 24 hours post LPS treatment) and glucose concentrations were persistently higher in GK+/- mice. We previously showed that LPS increased glucose permeability across *ex vivo* mouse trachea and *in vitro* which would increase glucose diffusion into ASL [[9](#_ENREF_9)]. We therefore suggest that glucose in ASL is metabolised by inflammatory cells and that increased glucose permeability during the inflammatory response increases glucose diffusion into ASL and this process may help sustain inflammatory cell function. During hyperglycaemia, the increased gradient for glucose diffusion would drive even more glucose into ASL resulting in the higher residual BALF glucose we observed after LPS treatment in GK+/- mice.

The increase in inflammatory cells correlated with elevation of pro-inflammatory cytokines and lactate. Lactate is involved in inflammatory cell signalling and is released at sites of inflammation by activated inflammatory cells. Its production is dependent on cellular glucose metabolism by inflammatory cells such as neutrophils [[27-29](#_ENREF_27)]. However, we also observed a small increase in BALF lactate (but not in cytokines or inflammatory cells) in untreated GK+/- compared to WT mice. We have evidence that hyperglycaemia elevates epithelial lactate secretion. This may therefore reflect a contribution from airway epithelial cells to lactate in BALF [[8](#_ENREF_8), [30-32](#_ENREF_30)].

Here we provide evidence that LPS elevated lactate concentration in the BALF of GK+/- mice was reduced compared to WT. Consistent with our results, peritoneal neutrophils from streptozotocin-treated diabetic rats exhibited reduced lactate production [[33](#_ENREF_33)]. In these neutrophils, the effect was reversed by insulin treatment. Insulin has also been shown to alter other LPS-induced inflammatory responses in diabetic rats [[34](#_ENREF_34)], yet the GK+/- mice used in this, and two other studies, had normal circulating plasma insulin levels [[14](#_ENREF_14), [16](#_ENREF_16)]. Thus, the role of luminal glucose concentration and insulin on inflammatory cell responses in these mice and in the lung needs further investigation.

LPS-treated GK+/- mice also exhibited decreased TNFα, IL-1β and IL-2 in the BALF compared to WT. Lower levels of TNFα and IL-1β were reported 4-6 hours after LPS challenge also in diabetic Wistar rats compared to WT [[13](#_ENREF_13), [35](#_ENREF_35)]. Similar to our findings, in one study this was independent of changes in neutrophils although in the other, this was not the case [[13](#_ENREF_13), [35](#_ENREF_35)]. TNFα and IL-1β are secreted by activated macrophages. Whilst, we did not see a significant reduction of macrophages in BALF, there is evidence that macrophage secretory function was impaired in LPS-challenged streptozotocin-induced diabetic mice [[36](#_ENREF_36)].

IL-2 is secreted by αβT-cells which are involved in endotoxin-induced airway inflammation [[37](#_ENREF_37)]. We cannot explain why IL-2 was reduced in the GK+/- mice after LPS treatment. Genes involved in IL-2 signalling are implicated in the development of type I diabetes and circulating levels are reduced in this disease [[38](#_ENREF_38)]. We did not measure plasma IL-2 and so cannot confirm whether this was the case in GK+/- mice. IL-2 is further involved in modifying cytokine secretion from other inflammatory cells. For example, human airway macrophages can be induced to produce TNFα in response to IL-2 [[39](#_ENREF_39)]. In addition, eosinophil degranulation is thought to be triggered by IL-2 [[38](#_ENREF_38)]. Thus, it is possible that the reduction of IL-2 in LPS-treated GK+/- mice leads to the reduction in the secretion of other cytokines and reduced eosinophil numbers at 24 hours.

**Conclusion**

Taken together, we show that acute LPS challenge in the mouse lung results in a reduction of BALF glucose concentration and elevation of inflammatory cells but that there is altered inflammatory cell responses in the lungs of GK+/- mice. We propose that glucose in the lung lumen is utilised by inflammatory cells during the inflammatory response. We showed previously that hyperglycaemia results in elevated ASL glucose and that this promotes the growth of respiratory pathogens in the lung. We also proposed a model for glucose homeostasis across the airway [[7](#_ENREF_7), [9](#_ENREF_9), [30](#_ENREF_30), [40](#_ENREF_40)]. We now propose a more complex model whereby, during infection, the inflammatory response competes with the airway epithelium and bacteria for glucose in the in the lung. Hyperglycaemia elevates glucose concentration in the lung lumen resulting in a bigger nutrient pool and an altered immune response. Recent findings in the upper airway also showed that glucose in the airway surface liquid may suppress anti-microbial peptide secretion [[41](#_ENREF_41), [42](#_ENREF_42)]. Thus, the balance that favours neutralisation of pathogens in normal lungs may shift to favour pathogen evasion/survival in lungs exposed to hyperglycaemia. Such changes may underlie the increased susceptibility to infection in patients with respiratory disease and diabetes (COPD/CF).

**Acknowledgements**

Funded by a Medical Research Council Industrial Collaboration Award with AstraZeneca Gothenburg, Sweden (MR/K012770/1).

**Authorship**

DB, EB, JT had the original concept for this work. AÅ, CN-H, JG, CW and GM designed the study, acquired and analysed the data. DB, AÅ, CN-H, GM and JT interpreted the data and compiled the work for publication.

**References**

1. Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Philips BJ. Hyperglycaemia and pulmonary infection. *Proc Nutr Soc* 2006: 65(3): 227-235.

2. Baker EH, Wood DM, Brennan AL, Baines DL, Philips BJ. New insights into the glucose oxidase stick test for cerebrospinal fluid rhinorrhoea. *Emerg Med J* 2005: 22(8): 556-557.

3. Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME, Philips BJ, Baines DL, Wood DM. Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. *J Appl Physiol* 2007: 102(5): 1969-1975.

4. Philips BJ, Redman J, Brennan A, Wood D, Holliman R, Baines D, Baker EH. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. *Thorax* 2005: 60(9): 761-764.

5. Wood DM, Brennan AL, Philips BJ, Baker EH. Effect of hyperglycaemia on glucose concentration of human nasal secretions. *Clin Sci (Lond)* 2004: 106(5): 527-533.

6. Baker E, Akunuri S, Morgan M, Greenaway S, O’Connor B, Ratoff J. Effect of airways inflammation and prednisolone treatment on BAL glucose concentrations in asthma and COPD patients. *Thorax* 2008: (Suppl VII): A40.

7. Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, Tregoning JS, Baines DL. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. *Thorax* 2013: 68(9): 835-845.

8. Garnett JP, Gray MA, Tarran R, Brodlie M, Ward C, Baker EH, Baines DL. Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. *PLoS One* 2013: 8(10): e76283.

9. Garnett JP, Nguyen TT, Moffatt JD, Pelham ER, Kalsi KK, Baker EH, Baines DL. Proinflammatory Mediators Disrupt Glucose Homeostasis in Airway Surface Liquid. *The Journal of Immunology* 2012: 189(1): 373-380.

10. Astrand A, Wingren C, Benjamin A, Tregoning JS, Garnett JP, Groves H, Gill S, Orogo-Wenn M, Lundqvist AJ, Walters D, Smith DM, Taylor JD, Baker EH, Baines DL. Dapagliflozin-lowered blood glucose reduces respiratory P. aeruginosa infection in diabetic mice. *Br J Pharmacol* 2017.

11. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, Hansen JM. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. *Am J Physiol Lung Cell Mol Physiol* 2014: 306(1): L43-49.

12. Wright JK, Nwariaku FN, Clark J, Falck JC, Rogers T, Turnage RH. Effect of diabetes mellitus on endotoxin-induced lung injury. *Arch Surg* 1999: 134(12): 1354-1358; discussion 1358-1359.

13. Boichot E, Sannomiya P, Escofier N, Germain N, Fortes ZB, Lagente V. Endotoxin-induced acute lung injury in rats. Role of insulin. *Pulm Pharmacol Ther* 1999: 12(5): 285-290.

14. Gorman T, Hope DC, Brownlie R, Yu A, Gill D, Lofvenmark J, Wedin M, Mayers RM, Snaith MR, Smith DM. Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice. *Diabetes Obes Metab* 2008: 10(10): 885-897.

15. Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LS, Holmes AH, Filloux A, Tregoning JS. Increased airway glucose increases airway bacterial load in hyperglycaemia. *Sci Rep* 2016: 6: 27636.

16. Terauchi Y, Kadowaki T. [Glucokinase knockout mice]. *Nihon Rinsho* 1998: 56 Suppl 3: 746-752.

17. Sakura H, Ashcroft SJ, Terauchi Y, Kadowaki T, Ashcroft FM. Glucose modulation of ATP-sensitive K-currents in wild-type, homozygous and heterozygous glucokinase knock-out mice. *Diabetologia* 1998: 41(6): 654-659.

18. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. *J Hered* 1950: 41(12): 317-318.

19. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. *Cell* 1996: 84(3): 491-495.

20. Knust J, Ochs M, Gundersen HJ, Nyengaard JR. Stereological estimates of alveolar number and size and capillary length and surface area in mice lungs. *Anat Rec (Hoboken)* 2009: 292(1): 113-122.

21. Song Y, Thiagarajah J, Verkman AS. Sodium and chloride concentrations, pH, and depth of airway surface liquid in distal airways. *J Gen Physiol* 2003: 122(5): 511-519.

22. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. *Proc Am Thorac Soc* 2004: 1(1): 42-46.

23. Siebert TA, Rugonyi S. Influence of liquid-layer thickness on pulmonary surfactant spreading and collapse. *Biophys J* 2008: 95(10): 4549-4559.

24. Johnston RA, Zhu M, Rivera-Sanchez YM, Lu FL, Theman TA, Flynt L, Shore SA. Allergic airway responses in obese mice. *Am J Respir Crit Care Med* 2007: 176(7): 650-658.

25. Harnish MJ, Lange T, Dimitrov S, Born J, Fehm HL. Differential regulation of human blood glucose level by interleukin-2 and -6. *Exp Clin Endocrinol Diabetes* 2005: 113(1): 43-48.

26. De Boisblanc BP, Dobrescu C, Skrepnik N, Nelson S, Spitzer JJ, Bagby GJ. Compartmentalization of glucose utilization after intravenous vs. intratracheal challenge with LPS. *Am J Physiol* 1996: 270(3 Pt 1): L452-458.

27. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell* 2008: 134(5): 703-707.

28. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* 2014: 513(7519): 559-563.

29. Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. *J Clin Invest* 1982: 70(3): 550-557.

30. Kalsi KK, Baker EH, Fraser O, Chung YL, Mace OJ, Tarelli E, Philips BJ, Baines DL. Glucose homeostasis across human airway epithelial cell monolayers: role of diffusion, transport and metabolism. *Pflugers Arch* 2009: 457(5): 1061-1070.

31. Myerburg MM, King JD, Jr., Oyster NM, Fitch AC, Magill A, Baty CJ, Watkins SC, Kolls JK, Pilewski JM, Hallows KR. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. *Am J Respir Cell Mol Biol* 2010: 42(6): 676-684.

32. Garnett JP, Kalsi KK, Sobotta M, Bearham J, Carr G, Powell J, Brodlie M, Ward C, Tarran R, Baines DL. Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion. *Sci Rep* 2016: 6: 37955.

33. Alba-Loureiro TC, Hirabara SM, Mendonca JR, Curi R, Pithon-Curi TC. Diabetes causes marked changes in function and metabolism of rat neutrophils. *J Endocrinol* 2006: 188(2): 295-303.

34. Martins JO, Ferracini M, Anger DB, Martins DO, Ribeiro LF, Jr., Sannomiya P, Jancar S. Signaling pathways and mediators in LPS-induced lung inflammation in diabetic rats: role of insulin. *Shock* 2010: 33(1): 76-82.

35. Finnerty CC, Herndon DN, Przkora R, Pereira CT, Oliveira HM, Queiroz DM, Rocha AM, Jeschke MG. Cytokine expression profile over time in severely burned pediatric patients. *Shock* 2006: 26(1): 13-19.

36. Amano H, Yamamoto H, Senba M, Oishi K, Suzuki S, Fukushima K, Mukaida N, Matsushima K, Eguchi K, Nagatake T. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin-induced diabetes in mice. *Infect Immun* 2000: 68(5): 2925-2929.

37. Larsson R, Rocksen D, Lilliehook B, Jonsson A, Bucht A. Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation. *Infect Immun* 2000: 68(12): 6962-6969.

38. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. *Diabetes* 2012: 61(1): 14-22.

39. Strieter RM, Remick DG, Lynch JP, 3rd, Spengler RN, Kunkel SL. Interleukin-2-induced tumor necrosis factor-alpha (TNF-alpha) gene expression in human alveolar macrophages and blood monocytes. *Am Rev Respir Dis* 1989: 139(2): 335-342.

40. Garnett JP, Braun D, McCarthy AJ, Farrant MR, Baker EH, Lindsay JA, Baines DL. Fructose transport-deficient Staphylococcus aureus reveals important role of epithelial glucose transporters in limiting sugar-driven bacterial growth in airway surface liquid. *Cell Mol Life Sci* 2014: 71((23)): 4665-4673.

41. Lee RJ, Cohen NA. Bitter and sweet taste receptors in the respiratory epithelium in health and disease. *J Mol Med (Berl)* 2014: 92(12): 1235-1244.

42. Lee RJ, Kofonow JM, Rosen PL, Siebert AP, Chen B, Doghramji L, Xiong G, Adappa ND, Palmer JN, Kennedy DW, Kreindler JL, Margolskee RF, Cohen NA. Bitter and sweet taste receptors regulate human upper respiratory innate immunity. *J Clin Invest* 2014: 124(3): 1393-1405.

**Figure** **Captions**

**Figure 1.** Blood glucose **(a)**, blood lactate **(b)**, BALF glucose **(c)** and BALF lactate **(d)** concentrations in wild type (WT) (open symbols) and hyperglycaemic GK+/- mice (black symbols) before (circles) and after treatment with LPS for 4 (triangles), 24 (inverted triangles) and 48 hours (squares). Data are shown as individual measurements. Horizontal bars show mean±SEM. Significantly different from untreated WT control, \* p<0.05, significantly different from WT at similar time point, 130px-Dagger-and-double-dagger-in-times-new-roman.svg[1] p<0.05, significantly different from GK, + p<0.05.

**Figure 2.** Relationship between blood glucose and BALF glucose **(a)**, blood glucose and BALF lactate **(b)**, before (circles) and 48 hours after LPS treatment (squares) in WT (open) and GK+/- (black), respectively. Linear regression of the points before LPS treatment (-LPS) is shown as a solid black line and after LPS treatment (+LPS 48h) as a broken line. Relationship between total WBC measured in BALF and BALF glucose **(c)**, total WBC in BALF and BALF lactate **(d)** before (circles) and 48 hours after LPS treatment (squares) in WT (open) and GK+/- (black), respectively. Linear regression of the points from WT are shown as a solid line and GK+/- as a broken line.

**Figure 3.** Numbers of lymphocytes **(a)**, neutrophils **(b)**, macrophages **(c)** and eosinophils **(d)** in BALF from wild type (WT) (white symbols) and hyperglycaemic GK+/- mice (black symbols) before (circles) and after treatment with LPS for 4 (triangles), 24 (inverted triangles) and 48 hours (squares). Data are shown as individual measurements. Horizontal bars show mean±SEM. Significantly different from untreated control, \* p<0.05. Significantly different from WT at similar time point, 130px-Dagger-and-double-dagger-in-times-new-roman.svg[1] p<0.05.

**Figure 4.** Concentration of cytokines, TNFα **(a)**, INFγ **(b)**, IL-1β **(c)**, IL-2 **(d)**, IL-6 **(e)** and IL-8 **(f)** present in BALF from wild type (WT) (white symbols) and hyperglycaemic GK+/- mice (black symbols) before (circles) and after treatment with LPS for 48 hours (squares). Data are shown as individual measurements. Horizontal bars show mean±SEM. Significantly different from untreated control, \* p<0.05. Significantly different from WT at similar time point, 130px-Dagger-and-double-dagger-in-times-new-roman.svg[1] p<0.05.


**Figure 1**



**Figure 2**



**Figure 3**



**Figure 4**

